Conference Reports for NATAP

Back

EASL 43rd Annual Meeting of the European Association For The Study Of The Liver Milan, Italy April 23-27, 2008     SUSTAINED DURABILITY OF HBeAg SEROCONVERSION IN CHRONIC HEPATITIS B PATIENTS AFTER TREATMENT WITH TELBIVUDINE AND LAMIVUDINE - (05/28/08)   Virologic Responses to Peginterferon Alfa-2a/Ribavirin in Treatment-Naive Latino vs Non-Latino Whites Infected With HCV Genotype 1: The LATINO Study - (05/19/08)   Comparing Pegasys and PegIntron at EASL 2008 Milan - (05/16/08)   Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication... - (05/16/08)   Studies of the Potential for Resistance to Nitazoxanide or Tizoxanide in HCV Replicon-Containing Cell Lines - (05/16/08)   RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF NITAZOXANIDE IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 - (05/16/08)   EVALUATION OF A 4 WEEK LEAD-IN PHASE WITH NITAZOXANIDE PRIOR TO NITAZOXANIDE+PEGINTERFERON IN TREATING CHRONIC HEPATITIS C - (05/16/08)   Randomized Controlled Trial of Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and Peginterferon-Ribavirin in the Treatment of Patients with Chronic Hepatitis C Genotype 4 - (05/16/08)   Estimating the Likelihood of Sustained Virological Response in Chronic Hepatitis C (CHC) Therapy - (05/16/08)   R1626* (Prodrug of R1479) Demonstrates Potent Antiviral Activity Across HCV Genotypes 1-6 In Vitro - (05/16/08)   Regression of Cirrhosis Occurs & Prevents Death/Events - (05/16/08)   SVR Eradicates HCV - (05/16/08)   SVR Can Prevent HCC & Other Complications - (05/16/08)   SVR Reversed Cirrhosis in 21% - (05/16/08)   An open-label, comparative, multicentre study of peginterferon alfa-2a (40KD) plus ribavirin in the treatment of patients chronically infected with HCV/HBV or HCV alone - (05/15/08)   On-treatment HBsAg decline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40KD) therapy 3 years off-treatment: potential for response-guided therapy - (05/15/08)   HBV DNA suppression induced by peginterferon alfa-2a (40KD) but not by lamivudine results in HBsAg clearance and seroconversion at 3 years off-treatment - (05/15/08)   Efficacy and safety of peginterferon alfa-2a (40KD) in Chinese patients with HBeAg-positive chronic hepatitis B - (05/15/08)   Locteron Viral Kinetics and Anti-Viral Activity during Treatment with a Controlled-Release Interferon Alfa-2b in Genotype 1 Chronic Hepatitis C Patients - (05/06/08)   POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR, R7128, IN COMBINATION WITH PEG-IFN a-2a AND RIBAVIRIN - (05/06/08)   High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin - (05/06/08)   RVR & Ribavirin Dose Predict SVR - (05/02/08)   Biolex Therapeutics Researchers Present Locteron (controlled-release interferon alpha) Phase 2a Hepatitis C Trial Results at EASL Conference - (05/02/08)   EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY - (05/02/08)   Several Key Pegasys Studies at EASL 2008 - (05/02/08)   Association of Pre-Treatment and On-Treatment Factors With Null Response in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin - (05/02/08)   Sustained Virologic Response After Peginterferon alfa-2b and Ribavirin Treatment Predicts 99% Long-term Clearance of HCV at 5-Year Follow-up - (05/02/08)   Platelet Count (and fibrosis stage) Predicts Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin (I/R) Non-Responders (NR): Results from the EPIC3 Program - (05/02/08)   Treatment of Chronic Hepatitis C with Telaprevir (TVR) in Combination with Peginterferon Alfa-2a with or without Ribavirin: Interim Results of the PROVE2 Study - (05/02/08)   NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease - (05/02/08)   Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with PEGASYS with or without lamivudine: results of 4-year follow-up: 11% HBsAg Clearance - (05/02/08)   SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)   Results of a Safety, Tolerability and Pharmacokinetic Phase I Study of VCH-916, a Novel Polymerase Inhibitor for HCV, Following Single Ascending Doses in Healthy Volunteers - (05/02/08)   Preclinical Pharmacokinetic and ADME Characterization of VCH-916, a Novel Non-Nuclesoside HCV NS5B Polymerase Inhibitor - (05/02/08)   Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759, and Viral Load Declines - (05/02/08)   Entecavir (ETV) Results in Higher HBV DNA Reduction versus Adefovir (ADV) in Antiviral-naive HBeAg(+) Adults with High HBV DNA: Week 96 Results (E.A.R.L.Y. Study) - (05/01/08)   Important Progress Toward Control of Hepatitis B and C - (05/01/08)   Incidence Rates and Risk Factors Associated with Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease Due to Hepatitis C: Results of the HALTC Trial; Is the HALT-C Study Design Flawed??? - (05/01/08)   Increasing HBV Viral Load Increases Risk for Liver Cancer--Serial Monitoring of Viral load and Serum Alanine Aminotransferase (ALT) Level and the Risk of Hepatocellular Carcinoma: R.E.V.E.A.L- HBV Study Update - (04/30/08)   Three Years of Continuous Treatment with Entecavir Results in High Proportions of Chinese Nucleoside-Naive Patients with Undetectable HBV DNA: Results from Studies ETV-023 and -050 - (04/30/08)   Three Years of Continuous Treatment in Chinese Patients who had Previously Failed Lamivudine: Results from Studies ETV-056 and ETV-050 - (04/30/08)   Long Term (3 Years) Efficacy, Safety and Resistance Analyses of Entecavir (ETV) Treatment in Japanese Nucleoside-naive Patients with Chronic Hepatitis B (CHB) - (04/30/08)   Interim Results from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naive Subjects with Genotype-1 CHC - (04/30/08)   DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY - (04/30/08)   New HCV Drugs Panel Discussion at EASL 2008 - (04/30/08)   Boceprevir (NS3 Protease Inhibitor) Combination Therapy in Non Responders: Phase II Dose Finding Study - (04/30/08)   Sustained Viral Response Is Dependent On Baseline Characteristics In The Re-treatment Of Previous Interferon/Ribavirin Non-responders: Final Results From The EPIC3 Program - (04/30/08)   Romark Announces Presentation of New Data For Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/29/08)   Increasing Serial HBV Viral Load & ALT Predicts HCC - (04/29/08)   BARACLUDE (ENTECAVIR) TREATMENT RESULTED IN GREATER VIRAL LOAD SUPPRESSION COMPARED TO ADEFOVIR AT 96 WEEKS IN ANTIVIRAL-NAIVE ADULT CHRONIC HEPATITIS B E-ANTIGEN POSITIVE PATIENTS - BMS press release - (04/29/08)   Hepatitis B an issue 'too hot to handle' in Australia - (04/29/08)   A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV MONO-INFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOGUE EXPERIENCE - (04/29/08)   The Antiviral Response To Tenofovir Disoproxil Fumarate (TDF) is Comparable in Lamivudine (LAM)-NaIve and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB) - (04/29/08)   Tenofovir Disoproxil Fumarate (TDF) is Highly Active for Treatment of Chronic Hepatitis B (CHB) in Patients With Cirrhosis - (04/29/08)   Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) - (04/29/08)   Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103) - (04/29/08)   Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)   Liver Disease Progression in Chronic Hepatitis B Infected Persons With Persistently Normal Serum Alanine Aminotransferase Level: Update From the R.E.V.E.A.L.-HBV Study - (04/29/08)   Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) - (04/29/08)   Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C - (04/28/08)   Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study - (04/28/08)   Potent Antiviral Activity of 2nd Generation HCV Nucleotide Inhibitors, IDX102 and IDX184, in HCV-infected Chimps - (04/28/08)   In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors - (04/28/08)   HALT-C Study Design Flawed - (04/28/08)   Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients - (04/28/08)   Peginterferon Alfa-2a (Pegasys) plus Ribavirin versus Peginterferon alfa-2b (Pegintron) Plus Ribavirin in Naive Patients with Chronic HHCV Infection: Results of a Prospective Randomized Trial - (04/28/08)   Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy) - (04/28/08)   ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER - (04/25/08)   Safety of the HCV Protease Inhibitor TMC435350 in Healthy Volunteers and Safety and Activity in Chronic Hepatitis C Infected Individuals: A Phase I Study - (04/25/08)   NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY - (04/25/08)   European Commission Approves Viread(R) for Chronic Hepatitis B - (04/25/08)   HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C - (04/25/08)   A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results - (04/25/08)   Study shows positive findings in treating patients with advanced hepatitis C - (04/25/08)   COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL - (04/25/08)   FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION - (04/25/08)   RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL) - (04/25/08)   Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment - (04/24/08)   Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments - (04/24/08)   GILEAD ANNOUNCES 72-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD (tenofovir) FOR THE TREATMENT OF CHRONIC HEPATITIS B - (04/24/08)   NEW HCV DRUGS at EASL Apr 23-27, 2008 Milan - (04/23/08)   Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/23/08)   HCV Drug Resistance - (04/23/08)